Development of new classes of bio-relevant linkers for PROTACs and other conjugates using new technologies - Year two

Les PROTACs sont de nouvelles molécules thérapeutiques ayant pour but de soigner certaines maladies grave comme les cancers. Ces composés sont des molécules linéaires constitués de trois composants principaux : une extrémité permettant de repérer la cible, une autre extrémité permettant de causer la dégradation de cette cible, et enfin un linker reliant les deux. Cette dernière partie est la moins étudié, bien qu’il ait récemment été prouvé qu’elle joue grandement sur les propriétés de la molécule finale.

Development of a clinical protocol for the validation of a detection test for ??amyloid aggregates in retinal scan images.

Alzheimer’s disease (AD) is a neurodegenerative disorder that is difficult to detect early before apparent manifestations of cognitive decline. Current detection methods rely on expensive and hardly accessible imaging techniques (PET scans). Optina Diagnostics developed a new camera as well as innovative image processing methods to propose a non-invasive test to identify the presence of AD biomarkers in evaluated individuals. The objective of this collaborative effort is to develop a clinical protocol to test this new technology.

Sex: It’s a matter of the heart

Heart failure is a complex cardiovascular disease with increasing global burden while the prognosis for patients remains poor. Risk factors and the type of heart failure differ between men and women. These differences can be due to sex – referring to biological differences – or gender – referring to social differences. In our project we will study the role of genetics in the different types of heart failure in men and women, using models that distinguish the contribution of both sex and gender.

Efficient and low-complexity video coding for virtual reality and 360-degree video streaming

Virtual reality (VR) and augmented reality (AR) offer a unique immersive video experience by providing 360-degree video in a panoramic view. Limited bandwidth, demanding high quality, encoder delay, network latency and lack of standards are the main problems to deliver true VR immersive experience.

Elaboration of a Phase II clinical study protocol for the treatment of metastatic non-small cell lung cancer (NSCLC) using AB-16B5, an epithelial to mesenchymal transition (EMT) inhibitor, in combination with docetaxel

The molecular mechanisms responsible for the occurrence of metastatic cancer are beginning to be elucidated with the identification of key regulators. Increasing evidence points to tumor cell epithelial to mesenchymal transition (EMT) as an important contributing process to metastatic evolution. The identification of factors that are stimulated during EMT might provide the means to develop new drugs required to increase the effectiveness of current regimens and improve patient outcome.

Modeling regime changes to improve portfolio diversification and performance

Asset allocation – the decision of how to divide a portfolio among the major asset classes such as cash, stocks and bonds – is a key determinant of portfolio performance. Because financial markets go through periods of strong and weak economies, the performance of an asset class varies with shifting economic conditions. These regime shifts pose a challenge to the asset allocation decision because they impact the portfolio’s return and risk.

Development and validation of BRET-based biosensors for drug candidate profiling

G protein coupled receptors (GCPRs) are proteins found at the surface of cells are responsible for activating numerous intracellular signaling pathways and thus are involved in regulating about every physiological response. Activation of GPCRs occurs by compounds as varied as photons, lipids, ions, small hormonal or neurotransmitter compounds or larger peptidic and protein molecules. As such, GPCRs are currently the target of up to 34% of marketed drugs.

Cold plasma therapy as adjuvant to radiotherapy for breast cancer treatment

The goal of this research is to improve breast cancer local control and reduce treatment side effects by demonstrating that a new cold plasma technology, which generates locally specific reactive oxygen species, has an additive positive treatment impact when combined with conventional radiotherapy. This project has the potential to enable a Canadian technology, to become an adjuvant for radiotherapy.

Québec__Université de Montréal

No additional funding contribution is required from the academic supervisor or university.
Fellowships will be awarded competitively.

Implementation of a chip-based MDTMA platform for evaluating prostate cancer treatment response and mode of action. - Year two

Prostate cancer is the disease of the old, effecting 1 in 7 Canadians with a death burden of 1 in 28. The management of the disease becomes extremely difficult with the development of the nonresponsive and aggressive form of the cancer. Thus, the clinicians are rendered helpless and hence there is an urgent need for the development of new targeted therapies. Response to chemotherapy drugs varies for every individual, leading to adverse effects in many. Hence every individual responds to chemotherapy drugs differentially, matching the right dose for individual patient is a big challenge.